Projects

IrsiCaixa is involved in a hundred national and international research projects active each year, funded by both public and private entities.

Keywords

Research group

Researcher

From date

To date

Restoring the intestinal microbiome composition and function with dolutegravir vs. darunavir/ritonavir

Project status

Ongoing

Start/End

2017

/

2021

Principal investigator

Roger Paredes

Financing entity

Viiv Healthcare
Allogeneic stem cell transplantation in HIV-1 infected individuals and 1st ITATI strategy

Project status

Ongoing

Start/End

2018

/

2020

Principal investigator

Javier Martínez-Picado

Participating entities

Foundation for AIDS Research amFAR (ARCHE program); ref 109858-64-RSRL
miRNA - Circulating microRNAs as biomarkers of liver disease progression in HIV infected individuals

Project status

Ongoing

Start/End

2018

/

2023

Financing entity

Grifols
Desarrollo de un diagnóstico precoz mediante biopsias líquidas y desarrollo de una vacuna innovadora para combatir el cáncer de páncreas metastásico.

Project status

Ongoing

Start/End

2020

/

2023

Financing entity

Sorigué
Estrategias inmunes frente a la persistencia del VIH

Project status

Ongoing

Start/End

2020

/

2022

Principal investigator

Bonaventura Clotet Sala

Financing entity

Instituto de Salud Carlos III (ISCIII); Fondo Europeo de Desarrollo Regional (FEDER) – Una manera de hacer Europa

Referencia del proyecto: PI19/00194

Finançament: Instituto de Salud Carlos III (ISCIII); Fondo Europeo de Desarrollo Regional (FEDER) – Una manera de hacer Europa
Identification and characterization of elite controller mechanisms in HIV infection

Project status

Ongoing

Start/End

2014

/

2016

Principal investigator

Bonaventura Clotet Sala

Participating entities

IrsiCaixa AIDS Research Institute

Financing entity

Ministry of the Economy and Competitiveness - Carlos III Health Institute (ISCIII) - FEDER. PI13/01083

The project aims to assess the role of HIV-1 infection restriction factors as crucial elements in disease progression. Preliminary results suggest differing infection restriction regulation in HIV-1-positive patients with differing progression rates. This project will result in the validation of new infection control and monitoring markers for the post-HAART era and the identification of strategies aimed at reducing chronic activation in HIV-positive patients.
Translational study of Inhibitory Receptors in HIV-1 infection: Identification of novel immunotherapeutic targets to reverse T-cell immune exhaustion

Project status

Ongoing

Start/End

2018

/

2020

Principal investigator

Julia García Prado

Participating entities

Institut de Recerca de la Sida IrsiCaixa

Financing entity

Ministry of the Economy, Industry and Competitiveness - Carlos III Health Institute (ISCIII) – FEDER. PI17/00164
Treatment with immunological checkpoint inhibitors of HIV-infected subjects with cancer

Project status

Ongoing

Start/End

2018

/

2023

Principal investigator

Javier Martínez-Picado

Financing entity

Merck Sharp & Dohme de España, SA (MSD); ref IISP 57699
Identificación, aislamiento y caracterización de anticuerpos que interfieren con la acción de los anticuerpos neutralizantes en personas infectadas por el virus de la inmunodeficiencia humana

Project status

Ongoing

Start/End

2019

/

2021

Principal investigator

Jorge Carrillo Molina

Financing entity

Ministry of Science, Innovation and Universities – Carlos III Health Institute (ISCIII) – FEDER - PI18/01332
Aging with HIV infection: causes and consequences of the premature immunoaging

Project status

Ongoing

Start/End

2020

/

2022

Principal investigator

Marta Massanella Luna

Strategic lines

Cancer

Emerging infectious diseases